<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40756">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02575807</url>
  </required_header>
  <id_info>
    <org_study_id>ADU-CL-11</org_study_id>
    <nct_id>NCT02575807</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian, or Peritoneal Cancer</brief_title>
  <acronym>SEASCAPE</acronym>
  <official_title>A Phase 1/2, Open-Label Safety and Efficacy Evaluation of CRS-207 in Combination With Epacadostat in Adults With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aduro Biotech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Aduro Biotech, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This 2-part, phase 1/2 trial examines the side effects of cancer immunotherapy with CRS-207
      alone and in combination with epacadostat (INCB024360), an indoleamine 2,3-dioxygenase
      (IDO1) inhibitor, and to see how well they work in treating patients with ovarian, fallopian
      tube, or peritoneal cancer who progressed on a platinum-based chemotherapy within 6 months.
      CRS-207 is a weakened (attenuated) form of Listeria monocytogenes that has been genetically
      modified to reduce its ability to cause disease, while maintaining its ability to stimulate
      potent immune response to kill tumor cells. Epacadostat is a potent, highly selective IDO1
      inhibitor which stimulates immune cell activation in tumors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Number of patients reporting treatment-related adverse events that qualify as dose-limiting toxicities</measure>
    <time_frame>approximately 12 months from study start</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Adverse events by CTCAE grade</measure>
    <time_frame>approximately 12 months from study start</time_frame>
    <description>CTCAE=common terminology criteria for adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Ratio of tumor infiltrating lymphocytes CD8/Treg (FoxP3)</measure>
    <time_frame>approximately 12 months from study start</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Plasma kynurenine/tryptophan ratio</measure>
    <time_frame>approximately 12 months from study start</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: ORR will be measured, defined as CR or PR as determined by mRECIST</measure>
    <time_frame>approximately 24 months from initiation of Part 2</time_frame>
    <description>ORR=overall response rate, CR=complete response, PR=partial response, mRECIST=modified response evaluation criteria in solid tumors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: PFS will be measured, defined as the time from the date of first dose to PD or death due to any cause</measure>
    <time_frame>approximately 24 months from initiation of Part 2</time_frame>
    <description>PFS=progression-free survival, PD=disease progression</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Platinum-resistant Ovarian Cancer</condition>
  <condition>Platinum-resistant Fallopian Cancer</condition>
  <condition>Platinum-resistant Peritoneal Cancer</condition>
  <arm_group>
    <arm_group_label>Part 1 &amp; 2: Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CRS-207 + epacadostat</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 &amp; 2: Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CRS-207</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Epacadostat</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CRS-207</intervention_name>
    <description>via IV infusion</description>
    <arm_group_label>Part 1 &amp; 2: Arm 1</arm_group_label>
    <arm_group_label>Part 1 &amp; 2: Arm 2</arm_group_label>
    <other_name>Live-attenuated, double-deleted (LADD) Listeria monocytogenes</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epacadostat (INCB024360)</intervention_name>
    <description>PO BID</description>
    <arm_group_label>Part 1 &amp; 2: Arm 1</arm_group_label>
    <arm_group_label>Part 1: Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with histologically-confirmed platinum-resistant epithelial ovarian,
             fallopian, or primary peritoneal cancer with disease progression within 6 months
             after completing platinum based chemotherapy

          -  Has measurable/assessable disease as defined by RECIST v1.1

               -  Part 1: tumor must be accessible and safe to biopsy at baseline

               -  Part 2: subjects musts agree to have paired tumor biopsies of lesion at baseline
                  and on treatment if the lesion can be biopsied with acceptable clinical risk (as
                  judged by the investigator)

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

        Exclusion Criteria

          -  Has platinum-refractory disease (progression during prior platinum-based
             chemotherapy);

          -  Had a major surgical procedure within 4 weeks prior to dosing

          -  Has clinically significant ascites

          -  Prior chemotherapy regimens

               -  Part 1: had a previous treatment with &gt;4 chemotherapy regimens for locally
                  advanced or metastatic disease

               -  Part 2: had a previous treatment with &gt;2 chemotherapy regimens for locally
                  advanced or metastatic disease

          -  Prior monoclonal antibody within 4 weeks before study Day 1

          -  Has a history of listeriosis or previous treatment with a listeria-based
             immunotherapy

          -  Has a known allergy to both penicillin and sulfa antibiotics

          -  Has any immunodeficiency disease or immune-compromised state

          -  Has a history of any autoimmune disease

          -  received prior immune checkpoint inhibitors (e.g., anti-CTLA-4, anti-PD-1, anti
             PDL-1) and any other antibody or drug specifically targeting T-cell costimulation or
             an IDO inhibitor

          -  History of organ transplant that requires use of immunosuppressive therapy

          -  Has prosthetic heart valves; major implant(s) or device(s) placed within 12 months of
             screening; or current or prior history of infection or clinically significant adverse
             events associated with implant(s) or device(s) that cannot be easily removed

          -  Currently receiving therapy with a UDP-glucuronosyltransferase 1A9 inhibitor
             including diclofenac, imipramine, ketoconazole, mefenamic acid, and probenecid

          -  Receiving monoamine oxidase inhibitor (MAOIs) or a drug which has significant MAOI
             activity (meperidine, linezolid, methylene blue) within the 21 days before screening

          -  Had prior serotonin syndrome

          -  Has clinically significant heart disease

          -  History of presence of abnormal ECG that is considered clinically meaningful

          -  Is pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Incyte Corporation Call Center</last_name>
    <phone>1-855-463-3463</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Scottsdale Healthcare Hospitals DBA HonorHealth</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joyce Schaffer, MSN, RN, AOCNS</last_name>
      <phone>480-323-1339</phone>
      <email>clinicaltrials@honorhealth.com</email>
    </contact>
    <investigator>
      <last_name>Jasgit Sachdev, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Lindblad, RN, BSN</last_name>
      <phone>352-265-0680</phone>
      <phone_ext>58127</phone_ext>
    </contact>
    <investigator>
      <last_name>Merry J Markham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Swetzig</last_name>
      <phone>312-472-5727</phone>
      <email>wendy.swetzig@northwestern.edu</email>
    </contact>
    <contact_backup>
      <last_name>Rebecca Samuels</last_name>
      <phone>312-472-5726</phone>
      <email>rebecca.samuels@northwestern.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Daniela Matei, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maureen Berg, RN, OCN</last_name>
      <phone>443-287-6602</phone>
    </contact>
    <investigator>
      <last_name>Leisha A Emens, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Knight Clinical Trials Office</last_name>
      <phone>503-494-1080</phone>
      <email>trials@ohsu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Health System</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cathi Ybarra, BSN, RN</last_name>
      <phone>215-614-0234</phone>
      <email>Cathi.Ybarra@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Janos L Tanyi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosanne Clayton</last_name>
      <phone>215-214-3904</phone>
      <email>rosanne.clayton@fccc.edu</email>
    </contact>
    <investigator>
      <last_name>Lainie Martin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Gabel</last_name>
      <phone>434-982-6657</phone>
      <email>am7bd@virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Linda R Duska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison Singer, CCRC</last_name>
      <phone>206-342-6910</phone>
      <email>ASinger@benaroyaresearch.org</email>
    </contact>
    <investigator>
      <last_name>Amy D Brockmeyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geraldine Prendergast</last_name>
      <phone>416-946-4501</phone>
      <phone_ext>4365</phone_ext>
      <email>gerry.prendergast@uhn.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHUM - Centre Hospitalier de l'Université de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnaud Villier</last_name>
      <email>arnaud.villier.chum@ssss.gouv.qc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Bonny Choy</last_name>
      <email>bonny.choy.chum@ssss.gouv.qc.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 16, 2016</lastchanged_date>
  <firstreceived_date>October 12, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ovarian cancer</keyword>
  <keyword>Fallopian cancer</keyword>
  <keyword>Primary peritoneal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
